These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 10609496

  • 41. Matrix Metalloproteinases and Their Tissue Inhibitors in Blood Serum of Patients with Endometrial Cancer: Clinical and Morphological Correlations.
    Gershtein ES, Mushtenko SV, Ermilova VD, Levchenko NE, Kushlinskii NE.
    Bull Exp Biol Med; 2018 May; 165(1):75-79. PubMed ID: 29796809
    [Abstract] [Full Text] [Related]

  • 42. Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
    Kikuchi H, Shimada W, Nonaka T, Ueshima S, Tanaka S.
    Clin Exp Pharmacol Physiol; 1996 May; 23(10-11):885-9. PubMed ID: 8911730
    [Abstract] [Full Text] [Related]

  • 43. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
    Ramón L, Gilabert-Estellés J, Castelló R, Gilabert J, España F, Romeu A, Chirivella M, Aznar J, Estellés A.
    Hum Reprod; 2005 Jan; 20(1):272-8. PubMed ID: 15579491
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Neutral proteinases and their inhibitors in the loosening of total hip prostheses.
    Takagi M.
    Acta Orthop Scand Suppl; 1996 Oct; 271():3-29. PubMed ID: 8975533
    [Abstract] [Full Text] [Related]

  • 46. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
    Reinartz J, Schaefer B, Bechtel MJ, Kramer MD.
    Exp Cell Res; 1996 Feb 25; 223(1):91-101. PubMed ID: 8635500
    [Abstract] [Full Text] [Related]

  • 47. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
    Belkacemi L, Lam E, Caldwell JD, Siemens DR, Graham CH.
    Exp Cell Res; 2006 Jun 10; 312(10):1685-92. PubMed ID: 16564525
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.
    Tanaka R, Saito T, Ashihara K, Nishimura M, Mizumoto H, Kudo R.
    Gynecol Oncol; 2003 Aug 10; 90(2):297-304. PubMed ID: 12893190
    [Abstract] [Full Text] [Related]

  • 51. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
    Lin SW, Ke FC, Hsiao PW, Lee PP, Lee MT, Hwang JJ.
    Exp Cell Res; 2007 Feb 01; 313(3):602-13. PubMed ID: 17187779
    [Abstract] [Full Text] [Related]

  • 52. Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
    Fujimoto J, Hori M, Ichigo S, Tamaya T.
    J Steroid Biochem Mol Biol; 1996 Sep 01; 59(1):1-8. PubMed ID: 9009232
    [Abstract] [Full Text] [Related]

  • 53. Expression and localization of extracellular matrix-degrading proteinases and their inhibitors in the bovine mammary gland during development, function, and involution.
    Rabot A, Sinowatz F, Berisha B, Meyer HH, Schams D.
    J Dairy Sci; 2007 Feb 01; 90(2):740-8. PubMed ID: 17235151
    [Abstract] [Full Text] [Related]

  • 54. Endothelin-1 promotes proteolytic activity of ovarian carcinoma.
    Rosanò L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A.
    Clin Sci (Lond); 2002 Aug 01; 103 Suppl 48():306S-309S. PubMed ID: 12193110
    [Abstract] [Full Text] [Related]

  • 55. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.
    Daneri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-Cuellar A, Perez-Montfort R, Orbach-Arbouys S.
    Eur J Cancer; 1998 Mar 01; 34(4):566-9. PubMed ID: 9713310
    [Abstract] [Full Text] [Related]

  • 56. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
    Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M, Terao T.
    Int J Cancer; 2002 Dec 01; 102(4):379-89. PubMed ID: 12402308
    [Abstract] [Full Text] [Related]

  • 57. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
    Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA, Yamamoto M, Kuroda Y, Itoh H.
    J Gastroenterol Hepatol; 2000 Apr 01; 15(4):422-30. PubMed ID: 10824888
    [Abstract] [Full Text] [Related]

  • 58. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
    Levicar N, Kos J, Blejec A, Golouh R, Vrhovec I, Frkovic-Grazio S, Lah TT.
    Cancer Detect Prev; 2002 Apr 01; 26(1):42-9. PubMed ID: 12088202
    [Abstract] [Full Text] [Related]

  • 59. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
    Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M.
    Int J Oncol; 1998 Nov 01; 13(5):893-906. PubMed ID: 9772277
    [Abstract] [Full Text] [Related]

  • 60. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C, Moses EK, Quinn MA, Rice GE.
    Gynecol Oncol; 2000 Nov 01; 79(2):244-50. PubMed ID: 11063652
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.